Clinical Trial Update: A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms [Phase 1]

View source ↗

Summary

This document announces that a Phase 1 study of fedratinib with an IDH inhibitor in IDH-mutated Philadelphia chromosome-negative myeloproliferative neoplasms ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-negative Myeloproliferative Neoplasms

Drugs mentioned

• IDH inhibitor
• INREBIC (fedratinib hydrochloride)

Snippet

Sponsor: University of Chicago | Conditions: IDH Mutation, IDH1 Mutation | Phase 1 | Status: WITHDRAWN